1-4 of 4
Allison Galanis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Allison Galanis, Hayley Ma, Trivikram Rajkhowa, Abhijit Ramachandran, Donald Small, Jorge Cortes, Mark Levis
Journal: Blood
Blood (2014) 123 (1): 94–100.
https://doi.org/10.1182/blood-2013-10-529313
Published: 2014
Includes: Supplemental data
Journal Articles

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild-Type C-KIT and Potential Impact On Normal Hematopoiesis

Allison Galanis, Mark Levis, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3846.
https://doi.org/10.1182/blood.V122.21.3846.3846
Published: 2013
Journal Articles

Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations

Allison Galanis, Trivikram Rajkhowa, Chaitanya Muralidhara, Abhijit Ramachandran, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1341.
https://doi.org/10.1182/blood.V120.21.1341.1341
Published: 2012
Journal Articles

The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,

Elizabeth Burton, Ph.D., Bernice Wong, Jiazhong Zhang, Ph.D., Brian West, Ph.D., Gideon Bollag, Ph.D., Gaston Habets, Ph.D., Allison Galanis, Hoa Nguyen, Omotayo Arowojolu, Trivikram Rajhowa, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3632.
https://doi.org/10.1182/blood.V118.21.3632.3632
Published: 2011